Here are eight key points on the company’s financial report:
1. Net sales were up 36 percent to $5.6 million.
2. There were 18 BoneScalpel units consigned in the United States during the quarter, which is a 50 percent increase. Now there are 324 units installed in the United States total.
3. Revenue for the BoneScalpel in the United States was up 93 percent to $1.7 million in the second quarter.
4. The company received royalty payments from Covidien of around $1 million during the quarter.
5. Misonix’s net income was $901,000. That’s $0.11 earnings per diluted share during the second quarter, nearly doubled from the same period last year.
6. For the six-month’s end, the total revenue was up 41 percent to $10.1 million.
7. The revenue increase was due to a 50 percent increase in BoneScalpel revenue to $5.2 million and a 39 percent increase in SonaStar revenue at $3.1 million. The SonicOne revenue also increased 43 percent to $1.4 million in revenue.
8. Net income for the first half of the year was $1.3 million, or $0.16 earning per diluted share. The same period last year experienced a $425,000 net loss.
More articles on orthopedic devices:
27 spine devices receives FDA 510(k) clearance in January
NuVasive COO sells 15k shares—5 things to know
5 things to know about Mazor’s new vice president of international l sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
